Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
Authors:
- Keiichi TorimotoKTKeiichi Torimoto
- Yosuke OkadaYOYosuke Okada
- Hiroko MoriHMHiroko Mori
- Takashi OtsukaTOTakashi Otsuka
- Mayuko KawaguchiMKMayuko Kawaguchi
- Megumi MatsudaMMMegumi Matsuda
- Fumi KunoFKFumi Kuno
- Kei SugaiKSKei Sugai
- Satomi SonodaSSSatomi Sonoda
- Maiko HajimeMHMaiko Hajime
- Kenichi TanakaKTKenichi Tanaka
- Tadashi AraoTATadashi Arao
Open Access
- 18 February 2015
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 14 (1) , 25
Abstract
Basic studies have shown that glucagon-like peptide-1 (GLP-1) analogs exert a direct protective effect on the vascular endothelium in addition to their indirect effects on postprandial glucose and lipid metabolism. GLP-1 analogs are also reported to inhibit postprandial vascular endothelial dysfunction. This study examined whether the GLP-1 analog exenatide inhibits postprandial vascular endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). Seventeen patients with T2DM underwent a meal tolerance test to examine changes in postprandial vascular endothelial function and in glucose and lipid metabolism, both without exenatide (baseline) and after a single subcutaneous injection of 10 μg exenatide. Vascular endothelial function was determined using reactive hyperemia index (RHI) measured by peripheral arterial tonometry before and 120 min after the meal loading test. The primary endpoint was the difference in changes in postprandial vascular endothelial function between the baseline and exenatide tests. The natural logarithmically-scaled RHI (L_RHI) was significantly lower after the baseline meal test but not in the exenatide test. The use of exenatide resulted in a significant decrease in triglycerides (TG) area under the curve and coefficient of variation (CV). The change in L_RHI correlated with changes in CV of triglycerides and HDL-cholesterol. Multivariate analysis identified changes in triglyceride CV as the only determinant of changes in L_RHI, contributing to 41% of the observed change. Exenatide inhibited postprandial vascular endothelial dysfunction after the meal loading test, suggesting that exenatide has a multiphasic anti-atherogenic action involving not only glucose but also lipid metabolism. ClinicalTrials.gov: UMIN000015699 .Keywords
This publication has 33 references indexed in Scilit:
- Do incretins improve endothelial function?Cardiovascular Diabetology, 2014
- Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary reportCardiovascular Diabetology, 2013
- Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetesCardiovascular Diabetology, 2013
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering TherapiesDiabetes Care, 2010
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 DiabetesDiabetes Care, 2010
- Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes MellitusCurrent Diabetes Reports, 2010
- Molecular Insights and Therapeutic Targets for Diabetic Endothelial DysfunctionCirculation, 2009
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenJAMA, 2007
- Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAmerican Journal of Physiology-Endocrinology and Metabolism, 2004